263 related articles for article (PubMed ID: 10839461)
1. Urethanyl-3-amidinophenylalanine derivatives as inhibitors of factor Xa. X-ray crystal structure of a trypsin/inhibitor complex and modeling studies.
Sperl S; Bergner A; Stürzebecher J; Magdolen V; Bode W; Moroder L
Biol Chem; 2000 Apr; 381(4):321-9. PubMed ID: 10839461
[TBL] [Abstract][Full Text] [Related]
2. (R)-3-Amidinophenylalanine-derived inhibitors of factor Xa with a novel active-site binding mode.
Mueller MM; Sperl S; Stürzebecher J; Bode W; Moroder L
Biol Chem; 2002; 383(7-8):1185-91. PubMed ID: 12437104
[TBL] [Abstract][Full Text] [Related]
3. Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase.
Renatus M; Bode W; Huber R; Stürzebecher J; Stubbs MT
J Med Chem; 1998 Dec; 41(27):5445-56. PubMed ID: 9876114
[TBL] [Abstract][Full Text] [Related]
4. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.
Phillips G; Davey DD; Eagen KA; Koovakkat SK; Liang A; Ng HP; Pinkerton M; Trinh L; Whitlow M; Beatty AM; Morrissey MM
J Med Chem; 1999 May; 42(10):1749-56. PubMed ID: 10346927
[TBL] [Abstract][Full Text] [Related]
6. Identification and initial structure-activity relationships of a novel class of nonpeptide inhibitors of blood coagulation factor Xa.
Klein SI; Czekaj M; Gardner CJ; Guertin KR; Cheney DL; Spada AP; Bolton SA; Brown K; Colussi D; Heran CL; Morgan SR; Leadley RJ; Dunwiddie CT; Perrone MH; Chu V
J Med Chem; 1998 Feb; 41(4):437-50. PubMed ID: 9484495
[TBL] [Abstract][Full Text] [Related]
7. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
Quan ML; Ellis CD; Liauw AY; Alexander RS; Knabb RM; Lam G; Wright MR; Wong PC; Wexler RR
J Med Chem; 1999 Jul; 42(15):2760-73. PubMed ID: 10425087
[TBL] [Abstract][Full Text] [Related]
9. New inhibitors of thrombin and other trypsin-like proteases: hydrogen bonding of an aromatic cyano group with a backbone amide of the P1 binding site replaces binding of a basic side chain.
Lee SL; Alexander RS; Smallwood A; Trievel R; Mersinger L; Weber PC; Kettner C
Biochemistry; 1997 Oct; 36(43):13180-6. PubMed ID: 9341205
[TBL] [Abstract][Full Text] [Related]
10. Design of benzamidine-type inhibitors of factor Xa.
Gabriel B; Stubbs MT; Bergner A; Hauptmann J; Bode W; Stürzebecher J; Moroder L
J Med Chem; 1998 Oct; 41(22):4240-50. PubMed ID: 9784099
[TBL] [Abstract][Full Text] [Related]
11. Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors.
Shi Y; Sitkoff D; Zhang J; Klei HE; Kish K; Liu EC; Hartl KS; Seiler SM; Chang M; Huang C; Youssef S; Steinbacher TE; Schumacher WA; Grazier N; Pudzianowski A; Apedo A; Discenza L; Yanchunas J; Stein PD; Atwal KS
J Med Chem; 2008 Dec; 51(23):7541-51. PubMed ID: 18998662
[TBL] [Abstract][Full Text] [Related]
12. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
13. A novel factor Xa inhibitor: structure-activity relationships and selectivity between factor Xa and thrombin.
Katakura S; Nagahara T; Hara T; Iwamoto M
Biochem Biophys Res Commun; 1993 Dec; 197(2):965-72. PubMed ID: 8267636
[TBL] [Abstract][Full Text] [Related]
14. Co-crystal structure and inhibition of factor Xa by PD0313052 identifies structurally stabilized active site residues of factor Xa and prothrombinase.
Gould WR; Cladera E; Harris MS; Zhang E; Narasimhan L; Thorn JM; Leadley RJ
Biochemistry; 2005 Jul; 44(26):9280-9. PubMed ID: 15981994
[TBL] [Abstract][Full Text] [Related]
15. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
[TBL] [Abstract][Full Text] [Related]
16. Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa.
Mederski WW; Dorsch D; Anzali S; Gleitz J; Cezanne B; Tsaklakidis C
Bioorg Med Chem Lett; 2004 Jul; 14(14):3763-9. PubMed ID: 15203158
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors.
Schweinitz A; Dönnecke D; Ludwig A; Steinmetzer P; Schulze A; Kotthaus J; Wein S; Clement B; Steinmetzer T
Bioorg Med Chem Lett; 2009 Apr; 19(7):1960-5. PubMed ID: 19250826
[TBL] [Abstract][Full Text] [Related]
18. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of cancer chemopreventive Bowman-Birk inhibitor in ternary complex with bovine trypsin at 2.3 A resolution. Structural basis of Janus-faced serine protease inhibitor specificity.
Koepke J; Ermler U; Warkentin E; Wenzl G; Flecker P
J Mol Biol; 2000 May; 298(3):477-91. PubMed ID: 10772864
[TBL] [Abstract][Full Text] [Related]
20. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
